These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27642668)

  • 21. Characterization of immune responses induced by inactivated, live attenuated and DNA vaccines against Japanese encephalitis virus in mice.
    Li J; Chen H; Wu N; Fan D; Liang G; Gao N; An J
    Vaccine; 2013 Aug; 31(38):4136-42. PubMed ID: 23845821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M; Kürsteiner O; Hilfiker H; Favre D; Durrer P; Ennaji A; L'Age-Stehr J; Kaufhold A; Herzog C
    Am J Trop Med Hyg; 2005 Mar; 72(3):339-46. PubMed ID: 15772332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
    Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
    Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].
    Gómez SY; Ocazionez RE
    Rev Salud Publica (Bogota); 2008; 10(5):796-807. PubMed ID: 19360228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.
    Oshansky CM; Wong SS; Jeevan T; Smallwood HS; Webby RJ; Shafir SC; Thomas PG
    mBio; 2014 Dec; 5(6):e02107. PubMed ID: 25491354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody response and maternal immunity upon boosting PRRSV-immune sows with experimental farm-specific and commercial PRRSV vaccines.
    Geldhof MF; Van Breedam W; De Jong E; Lopez Rodriguez A; Karniychuk UU; Vanhee M; Van Doorsselaere J; Maes D; Nauwynck HJ
    Vet Microbiol; 2013 Dec; 167(3-4):260-71. PubMed ID: 24041768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3
    Höschler K; Southern J; Thompson C; Warburton F; Andrews NJ; Miller E; Zambon M
    Vaccine; 2018 May; 36(21):3034-3040. PubMed ID: 29680198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.
    López P; Lanata CF; Zambrano B; Cortés M; Andrade T; Amemiya I; Terrones C; Gil AI; Verastegui H; Marquez V; Crevat D; Jezorwski J; Noriega F
    Pediatr Infect Dis J; 2016 Oct; 35(10):1140-7. PubMed ID: 27254034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.
    Hughes HR; Vincent AL; Brockmeier SL; Gauger PC; Pena L; Santos J; Braucher DR; Perez DR; Loving CL
    Clin Vaccine Immunol; 2015 Oct; 22(10):1109-20. PubMed ID: 26291090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-reactivity in flavivirus serology: new implications of an old finding?
    Allwinn R; Doerr HW; Emmerich P; Schmitz H; Preiser W
    Med Microbiol Immunol; 2002 Mar; 190(4):199-202. PubMed ID: 12005333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.